Company: INDP
Filing Date: 2025-03-27
Form Type: DRS
Source: 0001641172-25-000975
Chunk: 22

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-27
Form: DRS
Chunk 22
---
|:--|:----|:------------------------------|
| (U.S. dollars in thousands)                                                                            |     | Actual (audited)        |         |   |     | Pro               
 Forma (unaudited) |         |   |     | Pro                           
 Forma As Adjusted (unaudited) |
| Cash and cash equivalents                                                                              |     | $                       |   5,787 |   |     | $                 |   8,809 |   |     | $                             |
| Stockholders’ equity:                                                                                  |     |                         |         |   |     |                   |         |   |     |                               |
| Common stock: $0.01 par value, 200,000,000 shares authorized; issued and outstanding 12,013,901 shares 
 (actual), 15,829,244 (pro forma) and (pro forma as adjusted)                                           |     |                         |     120 |   |     |                   |     158 |   |     |                               |
| Additional paid in capital                                                                             |     |                         |  64,264 |   |     |                   |  67,248 |   |     |                               |
| Accumulated deficit                                                                                    |     |                         | (60,439 | ) |     |                   | (60,439 | ) |     |                               |
| Total stockholders’ equity                                                                             |     | $                       |   3,945 |   |     | $                 |   6,967 |   |     |                               |

Each $0.10 increase (decrease) in an assumed combined public offering price of $ per share and accompanying common warrant would increase (decrease) the amount of cash and cash equivalents and total stockholders’ equity by $ million, assuming that the number of shares and accompanying common warrants offered by us, as set forth on the cover page of this prospectus remains the same and after deducting the Placement Agent’s fees and estimated offering expenses payable by us. We may also increase or decrease the number of shares and accompanying common warrants we are offering. An increase (decrease) of 100,000 in the number of shares we are offering would increase (decrease) the amount of cash and cash equivalents and total stockholders’ equity by $ million, after deducting the estimated Placement Agent’s fees and estimated offering expenses payable by us, assuming the assumed combined public offering price stays the same. The information discussed above is illustrative only and will adjust based on the actual combined public offering